Shares of BioTelemetry, Inc. (NASDAQ:BEAT) have been given a consensus recommendation of “Buy” by the nine analysts that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $43.50.
BEAT has been the subject of several analyst reports. Dougherty & Co reaffirmed a “buy” rating and issued a $40.00 price objective on shares of BioTelemetry in a research note on Wednesday, November 8th. SunTrust Banks initiated coverage on shares of BioTelemetry in a research note on Monday, October 23rd. They issued a “buy” rating and a $41.00 price objective for the company. BidaskClub raised shares of BioTelemetry from a “hold” rating to a “buy” rating in a research note on Wednesday, January 24th. Zacks Investment Research raised shares of BioTelemetry from a “strong sell” rating to a “hold” rating in a research note on Monday, January 22nd. Finally, Raymond James Financial initiated coverage on shares of BioTelemetry in a research note on Thursday, October 26th. They issued an “outperform” rating and a $37.00 price objective for the company.
BioTelemetry (NASDAQ:BEAT) traded up $0.58 during mid-day trading on Tuesday, hitting $34.25. 297,310 shares of the company traded hands, compared to its average volume of 379,161. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.48 and a current ratio of 1.60. BioTelemetry has a 1-year low of $23.30 and a 1-year high of $39.20. The firm has a market cap of $1,109.97, a price-to-earnings ratio of 26.55, a PEG ratio of 1.52 and a beta of 0.67.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.